Phase III Win for Boehringer Ingelheim & Click Therapeutics in Schizophrenia Digital Therapy

Phase III Win for Boehringer Ingelheim & Click Therapeutics in Schizophrenia Digital Therapy

By, Admin 11 August 2025

Big news in mental health innovation: Boehringer Ingelheim and Click Therapeutics announced that their pivotal Phase III CONVOKE study (NCT05838625) for CT-155 (BI 3972080)—an investigational prescription digital therapeutic (PDT). has met its primary endpoint.

What Was Studied

  • Goal: Evaluate CT-155 vs. a digital control app, as an adjunct to standard antipsychotic therapy.
  • Target Population: People with schizophrenia experiencing negative symptoms—a long-standing unmet need.
  • Primary Endpoint: Improvement in experiential negative symptoms from baseline to week 16, measured by the CAINS-MAP scale.
  • Duration: 16 weeks, randomized, double-blind, multicenter trial.

Key Outcomes

  • Primary endpoint met — clinically significant improvement in motivation and pleasure measures.
  • Safety: Well tolerated, no new safety concerns.
  • Breakthrough Device Designation granted in 2024 (U.S.).

Why It Matters

  • No U.S.-approved treatments currently exist for negative symptoms of schizophrenia.
  • About 60% of people with schizophrenia experience these symptoms, which include:
    - Experiential: lack of motivation, reduced social interaction, inability to feel pleasure
    - Expressive: blunted emotions, reduced speech
  • Economic toll: >$60 billion in U.S. direct healthcare costs (2019); higher costs and hospitalizations for patients with negative symptoms.

Voices from the Project

Emmanuelle Clerisme-Beaty, Medical Director US, Boehringer Ingelheim:

“This is an important moment for people living with the negative symptoms of schizophrenia… one of the largest unmet needs in mental health today.”

Shaheen Lakhan, MD, PhD, FAAN, Chief Medical & Scientific Officer, Click Therapeutics:

“These results mark the first Phase III evidence for a prescription digital therapeutic as an adjunct to standard therapy to address a core element of schizophrenia.”

Next Milestone

Full results will be presented at the 38th Annual ECNP Congress (Oct 13, Amsterdam) during the Novel Therapeutics Symposium.

About CT-155

  • Type: Prescription Digital Therapeutic (software-based, smartphone-delivered)
  • Function: Delivers interactive psychosocial interventions alongside antipsychotics
  • Advantages: Accessible anytime, addresses barriers such as cost and provider shortages, patient-centered flexibility

Companies at the Helm:

  • Boehringer Ingelheim – Global biopharma leader in high unmet medical need areas.
  • Click Therapeutics – Specializes in AI-driven, software-based prescription medical treatments.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!